子宮内膜症患者におけるビラプリサンの安全性と有効性を評価する

基本情報

NCT ID

NCT03573336

ステータス

中止

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

8

治験依頼者名

Bayer

概要

The primary objective of this study was to assess the efficacy and safety of two doses of vilaprisan compared to placebo in women with symptomatic endometriosis. The secondary objective of this study was to evaluate the safety and tolerability of two different doses of vilaprisan in women with symptomatic endometriosis. With the implementation of protocol version 4.0 dated 11-Dec-2018, no new subjects were enrolled. The objectives above cannot be reached as only limited data is available from subjects recruited before the temporary pause.

対象疾患

介入

依頼者（Sponsor）

実施施設 (4)